ELI LILLY & Co is 706.9x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($1.093 T vs $1.55 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AMLX | LLY |
|---|---|---|
| Market cap | $1.55 B | $1.093 T |
| US-listed rank | #2312 | #11 |
| Revenue (latest FY) | $0.00 | $65.18B |
| Net income (latest FY) | -$144.74M | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 53.0 |
| SEC filings | 403 | 989 |
ELI LILLY & Co is 706.9x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($1.093 T vs $1.55 B).
In their latest fiscal years, Amylyx Pharmaceuticals, Inc. reported $0.00 in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Amylyx Pharmaceuticals, Inc. and ELI LILLY & Co, or browse the full rankings.